Dermavant acquires compound from TheraVida

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) in-licensed from TheraVida Inc. (San Mateo, Calif.) rights to develop and commercialize hyperhidrosis candidate RVT-504 (formerly THVD-102). TheraVida will receive an upfront payment and is eligible for milestones and royalties.

TheraVida reported top-line Phase II data in October 2016 showing twice-daily 7.5/7.5 mg oral RVT-504 for 21 days significantly improved Hyperhidrosis Disease Severity Scale (HDSS), Hyperhidrosis Visual Analog Scale (HHVAS) and Hyperhidrosis Visual Quantification Scale (HHVQS) scores compared to placebo in 24 patients with primary focal hyperhidrosis (see BioCentury, Oct. 24, 2016)...